for Health Care Providers
Table 1. Comparison of Side Effects in 3 Different HCV Treatment Regimens from Randomized Controlled Clinical Trials
Peginterferon alfa-2b 1.5 mcg/kg weekly + Ribavirin 800 mg daily
Manns, et al. The Lancet, 2001(3)
(N = 511)
Peginterferon alfa-2a 180 mcg weekly + Ribavirin 1000-1200 mg daily, weight based
Fried, et al. NEJM, 2002(4)
(N = 453)
Interferon alfa-2b 3 million units three times weekly + Ribavirin 1000-1200 mg daily, weight based
McHutchinson, et al. NEJM, 1998(2)
(N = 228)
|Adverse Event||(% Affected)|
# The % of patients with neutropenia was not reported or described, but authors included comment, "the leukocute counts decreased during therapy but the mean value remained within the normal range."
* The % of patients with thrombocytopenia was not reported, but authors included comment, "the median platelet counts decreased progressively during first either weeks of peginterferon 2a plus ribavirin, before stabilizing, After treatment was completed, the median platelet counts returned to normal within four weeks. 1 patient had serious bleeding and 4 discontinued treatment due to thrombocytopenia."